VHL (phospho Ser68) Polyclonal Antibody

Background:
von Hippel-Lindau tumor suppressor(VHL) Homo sapiens Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008],

Alternative Names:
VHL, Von Hippel-Lindau disease tumor suppressor, Protein G7, pVHL

Immunogen: The antiserum was produced against synthesized peptide derived from human VHL around the phosphorylation site of Ser68. AA range:34-83

Isotype: Rabbit

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration: 1 mg/ml

GeneID: VHL

Storage: -20°C/1 year

NOTE: For Research Use Only